Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia
Cancers · 21.07.2023 · 15 (14) · 3711
DOI: 10.3390/cancers15143711 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 21.07.2023. Verfasst von Øystein Bruserud und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Clinical Science, Faculty of Medicine, University of Bergen, 5021 Bergen, Norway. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Kreftforeningen, the Norwegian Cancer Society.
Abstract (Originalsprache)
The protein kinase CK2 (also known as casein kinase 2) is one of the main contributors to the human phosphoproteome. It is regarded as a possible therapeutic strategy in several malignant diseases, including acute myeloid leukemia (AML), which is an aggressive bone marrow malignancy. CK2 is an important regulator of intracellular signaling in AML cells, especially PI3K–Akt, Jak–Stat, NFκB, Wnt, and DNA repair signaling. High CK2 levels in AML cells at the first time of diagnosis are associated with decreased survival (i.e., increased risk of chemoresistant leukemia relapse) for patients receiving intensive and potentially curative antileukemic therapy. However, it is not known whether these high CK2 levels can be used as an independent prognostic biomarker because this has not been investigated in multivariate analyses. Several CK2 inhibitors have been developed, but CX-4945/silmitasertib is best characterized. This drug has antiproliferative and proapoptotic effects in primary human AML cells. The preliminary results from studies of silmitasertib in the treatment of other malignancies suggest that gastrointestinal and bone marrow toxicities are relatively common. However, clinical AML studies are not available. Taken together, the available experimental and clinical evidence suggests that the possible use of CK2 inhibition in the treatment of AML should be further investigated.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for Clinical Science, Faculty of Medicine, University of Bergen, 5021 Bergen, Norway.
- Section for Hematology, Department of Medicine, Haukeland University Hospital, 5021 Bergen, Norway.
ORCID-Profile: Håkon Reikvam
Förderung
- Wellcome Trust
- Kreftforeningen, the Norwegian Cancer Society
Zitieren
APA
Bruserud, Ø., & Reikvam, H. (2023). Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia. Cancers, 15(14), 3711. https://doi.org/10.3390/cancers15143711
Vancouver
Bruserud Ø, Reikvam H. Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia. Cancers. 2023;15(14):3711. doi:10.3390/cancers15143711
BibTeX
@article{Bruserud2023,
author = {Bruserud, Øystein and Reikvam, Håkon},
title = {Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia},
journal = {Cancers},
year = {2023},
volume = {15},
number = {14},
pages = {3711},
doi = {10.3390/cancers15143711}
}
EUVIMED